Anlotinib plus immunotherapy for advanced pheochromocytoma
Part of Cancer clinical trials.
This trial tests a combination of two drugs (anlotinib, a targeted therapy, and benmelstobart, an immunotherapy) for people with advanced pheochromocytoma or paraganglioma that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors or stop them from growing when other treatments are not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced pheochromocytoma or paraganglioma that has spread or come back, and you are not able or do not want standard chemotherapy or radioactive therapy.
- You have at least one tumor that can be measured on a scan.
- Your overall health and organ function (blood counts, liver, kidneys, clotting) must be adequate.
- You cannot have had certain previous treatments (such as anlotinib, PD-1/PD-L1 drugs, or other targeted anti-angiogenic drugs).
- You must not have serious heart conditions, active infections, or other major illnesses that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of anlotinib (a targeted therapy) and two chemotherapy drugs (nab-paclitaxel and S-1) for people with advanced bile duct cancer whose disease has worsened after first-line gemcitabine-based chemotherapy. The goal is to see if this combination can help shrink or control the tumor.
This trial tests a combination of two drugs (anlotinib and benmelstobart) as a first treatment for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if this combination helps control the cancer.
This trial tests a combination of two drugs, anlotinib (a targeted therapy) and benmelstobart (an immunotherapy), for people with differentiated thyroid cancer that has spread or cannot be removed. It may be an option if your cancer did not respond to or got worse after first treatment.
This trial tests a combination of anlotinib (a targeted drug), benmelstobart (an immunotherapy), and AG chemotherapy as a first treatment for advanced pancreatic cancer that has spread to other parts of the body. The goal is to see if this triple therapy can help shrink or control the cancer better than standard treatments.
This trial tests adding anlotinib (a targeted therapy) and benmelstobart (an immunotherapy) to standard chemotherapy before surgery for a specific type of breast cancer. It may help shrink tumors and improve outcomes for patients whose tumors have certain markers.
This trial tests a combination of two investigational drugs—anlotinib (a capsule that blocks blood supply to tumors) and TQB2450 (an immunotherapy that helps your immune system attack cancer cells)—for people with recurrent or metastatic endometrial cancer that has not responded to previous platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow their growth.
Hear when a new Pheochromocytoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.